Sort
1,049,261 grants matching “t cell”
Identifying protective omics profiles in centenarians and translating these into preventive and therapeutic strategies
$4,998,007Thomas T Perls · Boston University Medical Campus · UH3 · FY2022 · AG
Silent Cerebral Infarct Multi-Center Clinical Trial
$4,997,543Washington University · U01 · FY2003 · NS
The Center for HIV RNA Studies (CRNA)
$4,996,526Alice Telesnitsky · University Of Michigan At Ann Arbor · U54 · FY2018 · GM
DNA Sequencing Core
$4,996,343Yue-Sheng Li · National Heart, Lung, And Blood Institute · ZIC · FY2019 · HL
THE PROJECT OBJECTIVE IS TO DEVELOP ULTRA-LOW IR LOADING AND ULTRA-DURABLE OXYGEN EVOLUTION REACTION (OER) POWDER CATALYSTS FOR PROTON EXCHANGE MEMBRANE (PEM) WATER ELECTROLYZERS WHICH DEMONSTRATE EFFICIENCY AND DURABILITY MEETING OR EXCEEDING THE DOE TARGETS. THE OER POWDER CATALYSTS WILL BE INTEGRATED INTO OPTIMIZED HALF-CELL ARCHITECTURES DEFINED BY AN ELECTRODE, POROUS TRANSPORT LAYER (PTL), AND FLOW FIELD (FF), AND EVALUATED IN A FULL CELL ASSEMBLY OF 25CM2 ACTIVE AREA OR LARGER. THE EXPECTED OUTCOME IS ONE OR MORE ELECTROCATALYSTS VALIDATED TO REDUCE THE AMOUNT OF IR NEEDED TO MEET DEVICE EFFICIENCY AND LIFETIME REQUIREMENTS BY CA. 64X (ON A/MG BASIS) OVER CURRENT COMMERCIAL TECHNOLOGY.
$4,995,4913m Company · · FY2025 · Department of Energy
Cancer Center Support
$4,995,326University Of Pittsburgh At Pittsburgh · P30 · FY2005 · CA
TAS::89 0321::TAS IMPROVING FUEL CELL DURABILITY AND RELIABILITY INITIATIVE, UNIVERSITY OF CONNECTICUT
$4,994,724University Of Connecticut · · FY2010 · Department of Energy
First stage single-cell brain resource for Alzheimer's disease and related dementias
$4,993,814Andrew Singleton · National Institute On Aging · ZIA · FY2022 · AG
NEWBORN SCREENING TRANSLATIONAL RESEARCH NETWORK COORD CTR
$4,991,209Melissa Forburger · American College Of Medical Genetics · N01 · FY2012 · HD
Cardiovascular Injury and Repair Research Facility
$4,990,000Francis L Macrina · Virginia Commonwealth University · C06 · FY2009 · RR
UniProt: A centralized protein sequence and function resource
$4,987,860Alex Bateman · European Molecular Biology Laboratory · U41 · FY2017 · HG
Human Biochemical Genetics
$4,987,542William Gahl · National Human Genome Research Institute · ZIA · FY2020 · HG
COLD SPRING HARBOR LABORATORY CANCER RESEARCH CENTER
$4,987,374Cold Spring Harbor Laboratory · P01 · FY2004 · CA
Reversing Immune Dysfunction for HIV-1 Eradication
$4,986,752Sumit K Chanda · Scripps Research Institute, The · UM1 · FY2023 · AI
Molecular Basis of Cholesterol Metabolism
$4,986,672University Of Texas Sw Med Ctr/Dallas · P01 · FY2004 · HL
THE MAIN OBJECTIVE OF THIS PROJECT IS TO FURTHER DEVELOP AVIUM'S CATALYST TECHNOLOGY TO ACHIEVE 2 A CM-2 AT =1.7 V ON A 100 CM2 LIQUID ALKALINE (LA) ELECTROLYZER. TO ACHIEVE THIS OBJECTIVE WE WILL PERFORM THREE PARALLEL TASKS: (1) OPTIMIZE CATALYST GROWTH ONTO ELECTRODES AND LA SEPARATOR FOR MANUFACTURING HIGH CURRENT DENSITY SEAS, (2) 3D-MODEL- DRIVEN DESIGN OF CATALYST-COATED MESH ELECTRODE AND ELASTIC FLOW ELEMENT GEOMETRY TO BALANCE CATALYST ACTIVE AREA WITH MAINTAINING HIGH MASS TRANSFER AND 3D UTILIZATION, AND (3) DEVELOP AN IN SITU CATALYST REGENERATION PROTOCOL TO MAINTAIN AN EFFECTIVE DEGRADATION RATE OF =2.1 MV/KHR TO ENABLE A 100,000 H LIFETIME AT 2 A CM-2. THE OBJECTIVE FOR BUDGET PERIOD 1 IS TO DEVELOP A 15 CM2 SINGLE-CELL FLOW-THROUGH ELECTROLYZER THAT CAN ACHIEVE 1.95 V AT 2 A CM-2. THE OBJECTIVE FOR BUDGET PERIOD 2 IS TO DEVELOP A 100 CM2 SINGLE-CELL FLOW-THROUGH ELECTROLYZER THAT CAN ACHIEVE 1.85 V AT 2 A CM-2 AND DEMONSTRATE THE CAPABILITY TO RE-DEPOSIT CATALYSTS AND RECOVER PERFORMANCE AFTER A 50 MV DECREASE IN CELL VOLTAGE. THE OBJECTIVE FOR BUDGET PERIOD 3 IS A 100 CM2 SINGLE-CELL ELECTROLYZER THAT CAN ACHIEVE 2 A CM-2 AT =1.70 V WITH THE CAPABILITY TO REGENERATE AFTER 50 MV LOSS OF PERFORMANCE FROM ACCELERATED START/STOP CYCLES AND MEET AN EFFECTIVE DEGRADATION RATE OF =2.1 MV KHR-1 TO ENABLE >100,000 H LIFE TIME. THIS IS ALSO THE OVERALL OBJECTIVE FOR THIS PROJECT.
$4,985,214Avium, Llc · · FY2025 · Department of Energy
Reversing Immune Dysfunction for HIV-1 Eradication
$4,984,542Sumit K Chanda · Scripps Research Institute, The · UM1 · FY2022 · AI
Immunologic and Virologic Basis of RhCMV/SIV Vaccine-Induced Replication Arrest Efficacy
$4,983,192Louis J. Picker · Oregon Health & Science University · P01 · FY2022 · AI
THE UNIVERSITY OF PENNSYLVANIA CANCER CENTER CORE GRANT
$4,980,499University Of Pennsylvania · P30 · FY2000 · CA
Transcriptional Atlas of Human Brain Development
$4,973,911James A Knowles · University Of Southern California · RC2 · FY2009 · MH
Mayo Comprehensive Cancer Center Grant
$4,970,529Mayo Clinic · P30 · FY2005 · CA
Coriell Cell Engineering Center to Support National Biobanking Infrastructure
$4,969,509Nahid Turan · Coriell Institute For Medical Research · C06 · FY2025 · OD
Southern Liver Health Cohort
$4,968,641Cathrine Hoyo · North Carolina State University Raleigh · UH3 · FY2025 · CA
DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity
$4,966,751Paul Glyndwr Thomas · St. Jude Children'S Research Hospital · U01 · FY2020 · AI
BIL-COST EFFECTIVE, HIGH EFFICIENCY, INDUSTRIAL BACK CONTACT SILICON SOLAR CELLS WITH PASSIVATED CONTACTS A. PROJECT OBJECTIVES THE PRIMARY OBJECTIVE OF THE PROJECT IS TO DEVELOP BACK-CONTACT N-TYPE CELLS TO DEMONSTRATE EFFICIENCIES OF 26% OR BETTER ON A 300-MW PILOT SCALE, WHICH WILL OPERATE ALONGSIDE SILFAB’S MAIN N-TYPE CELL MANUFACTURING AT ITS FORT MILL, SOUTH CAROLINA FACILITY. THE PROJECT WILL ENABLE RAPID SCALE-UP OF COST EFFECTIVE, BACK-CONTACT CELL TECHNOLOGY INTO HIGH-VOLUME MANUFACTURING OF SILFAB’S NEXT LINE OF PREMIUM PV SOLAR MODULES.
$4,964,999Silfab Solar Cells Sc Inc · · FY2025 · Department of Energy